The Goto Kakizaki rat: Impact of age upon changes in cardiac and renal structure, function.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
12
2020
accepted:
20
05
2021
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
9
11
2021
Statut:
epublish
Résumé
Patients with diabetes are at a high risk for developing cardiac dysfunction in the absence of coronary artery disease or hypertension, a condition known as diabetic cardiomyopathy. Contributing to heart failure is the presence of diabetic kidney disease. The Goto-Kakizaki (GK) rat is a non-obese, non-hypertensive model of type 2 diabetes that, like humans, shares a susceptibility locus on chromosome 10. Herein, we perform a detailed analysis of cardio-renal remodeling and response to renin angiotensin system blockade in GK rats to ascertain the validity of this model for further insights into disease pathogenesis. Study 1: Male GK rats along with age matched Wistar control animals underwent longitudinal assessment of cardiac and renal function for 32 weeks (total age 48 weeks). Animals underwent regular echocardiography every 4 weeks and at sacrifice, early (~24 weeks) and late (~48 weeks) timepoints, along with pressure volume loop analysis. Histological and molecular characteristics were determined using standard techniques. Study 2: the effect of renin angiotensin system (RAS) blockade upon cardiac and renal function was assessed in GK rats. Finally, proteomic studies were conducted in vivo and in vitro to identify novel pathways involved in remodeling responses. GK rats developed hyperglycaemia by 12 weeks of age (p<0.01 c/w Wistar controls). Echocardiographic assessment of cardiac function demonstrated preserved systolic function by 48 weeks of age. Invasive studies demonstrated left ventricular hypertrophy, pulmonary congestion and impaired diastolic function. Renal function was preserved with evidence of hyperfiltration. Cardiac histological analysis demonstrated myocyte hypertrophy (p<0.05) with evidence of significant interstitial fibrosis (p<0.05). RT qPCR demonstrated activation of the fetal gene program, consistent with cellular hypertrophy. RAS blockade resulted in a reduction blood pressure(P<0.05) cardiac interstitial fibrosis (p<0.05) and activation of fetal gene program. No significant change on either systolic or diastolic function was observed, along with minimal impact upon renal structure or function. Proteomic studies demonstrated significant changes in proteins involved in oxidative phosp4horylation, mitochondrial dysfunction, beta-oxidation, and PI3K/Akt signalling (all p<0.05). Further, similar changes were observed in both LV samples from GK rats and H9C2 cells incubated in high glucose media. By 48 weeks of age, the diabetic GK rat demonstrates evidence of preserved systolic function and impaired relaxation, along with cardiac hypertrophy, in the presence of hyperfiltration and elevated protein excretion. These findings suggest the GK rat demonstrates some, but not all features of diabetes induced "cardiorenal" syndrome. This has implications for the use of this model to assess preclinical strategies to treat cardiorenal disease.
Sections du résumé
BACKGROUND
Patients with diabetes are at a high risk for developing cardiac dysfunction in the absence of coronary artery disease or hypertension, a condition known as diabetic cardiomyopathy. Contributing to heart failure is the presence of diabetic kidney disease. The Goto-Kakizaki (GK) rat is a non-obese, non-hypertensive model of type 2 diabetes that, like humans, shares a susceptibility locus on chromosome 10. Herein, we perform a detailed analysis of cardio-renal remodeling and response to renin angiotensin system blockade in GK rats to ascertain the validity of this model for further insights into disease pathogenesis.
METHODS
Study 1: Male GK rats along with age matched Wistar control animals underwent longitudinal assessment of cardiac and renal function for 32 weeks (total age 48 weeks). Animals underwent regular echocardiography every 4 weeks and at sacrifice, early (~24 weeks) and late (~48 weeks) timepoints, along with pressure volume loop analysis. Histological and molecular characteristics were determined using standard techniques. Study 2: the effect of renin angiotensin system (RAS) blockade upon cardiac and renal function was assessed in GK rats. Finally, proteomic studies were conducted in vivo and in vitro to identify novel pathways involved in remodeling responses.
RESULTS
GK rats developed hyperglycaemia by 12 weeks of age (p<0.01 c/w Wistar controls). Echocardiographic assessment of cardiac function demonstrated preserved systolic function by 48 weeks of age. Invasive studies demonstrated left ventricular hypertrophy, pulmonary congestion and impaired diastolic function. Renal function was preserved with evidence of hyperfiltration. Cardiac histological analysis demonstrated myocyte hypertrophy (p<0.05) with evidence of significant interstitial fibrosis (p<0.05). RT qPCR demonstrated activation of the fetal gene program, consistent with cellular hypertrophy. RAS blockade resulted in a reduction blood pressure(P<0.05) cardiac interstitial fibrosis (p<0.05) and activation of fetal gene program. No significant change on either systolic or diastolic function was observed, along with minimal impact upon renal structure or function. Proteomic studies demonstrated significant changes in proteins involved in oxidative phosp4horylation, mitochondrial dysfunction, beta-oxidation, and PI3K/Akt signalling (all p<0.05). Further, similar changes were observed in both LV samples from GK rats and H9C2 cells incubated in high glucose media.
CONCLUSION
By 48 weeks of age, the diabetic GK rat demonstrates evidence of preserved systolic function and impaired relaxation, along with cardiac hypertrophy, in the presence of hyperfiltration and elevated protein excretion. These findings suggest the GK rat demonstrates some, but not all features of diabetes induced "cardiorenal" syndrome. This has implications for the use of this model to assess preclinical strategies to treat cardiorenal disease.
Identifiants
pubmed: 34166385
doi: 10.1371/journal.pone.0252711
pii: PONE-D-20-39982
pmc: PMC8224913
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0252711Déclaration de conflit d'intérêts
The authors have read the journal’s policy and have the following competing interests: KAC has received research grants to his institution from Astra Zeneca and Boehringer Ingelheim, received support for travel to scientific meeting from Boehringer Ingelheim, and received honoraria for speaking engagements and ad hoc participation in advisory boards from Astra Zeneca, Boehringer Ingelheim, and Janssen. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
JAMA. 2001 Jul 25;286(4):421-6
pubmed: 11466120
J Diabetes Metab. 2013 May 30;Suppl 9(5):
pubmed: 24319624
Anal Chem. 2002 Oct 15;74(20):5383-92
pubmed: 12403597
Vasc Health Risk Manag. 2007;3(6):853-76
pubmed: 18200806
In Vitro Cell Dev Biol Anim. 2011 Feb;47(2):125-31
pubmed: 21082279
Circulation. 2017 Feb 21;135(8):736-740
pubmed: 28052978
Clin Res Cardiol. 2020 Feb;109(2):225-234
pubmed: 31267239
Cardiovasc Diabetol. 2018 Jul 7;17(1):99
pubmed: 29981571
Circulation. 2008 Jan 1;117(1):43-51
pubmed: 18071071
Sci Rep. 2016 Dec 21;6:39551
pubmed: 28000751
Anal Chem. 2003 Sep 1;75(17):4646-58
pubmed: 14632076
Diabetes Care. 2011 Apr;34(4):950-6
pubmed: 20622160
Cardiovasc Res. 2018 Oct 1;114(12):1629-1641
pubmed: 29800064
Cardiovasc Endocrinol. 2017 Feb 15;6(1):8-16
pubmed: 31646113
Eur Heart J. 2010 Mar;31(6):703-11
pubmed: 20037146
Circ Res. 1998 Sep 21;83(6):594-601
pubmed: 9742054
Circ Res. 2000 Dec 8;87(12):1123-32
pubmed: 11110769
Future Cardiol. 2020 Mar;16(2):77-88
pubmed: 31914812
Nat Rev Nephrol. 2010 Jun;6(6):319-30
pubmed: 20440277
Postgrad Med. 2018 Mar;130(2):149-153
pubmed: 29297732
Eur J Pharmacol. 2005 Sep 20;519(3):267-76
pubmed: 16137672
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Can J Cardiol. 2017 Mar;33(3):366-377
pubmed: 28340996
Int J Mol Sci. 2016 Dec 18;17(12):
pubmed: 27999359
N Engl J Med. 2013 Oct 3;369(14):1317-26
pubmed: 23992601
Circ Res. 2007 May 25;100(10):1415-27
pubmed: 17525381
J Clin Invest. 1994 May;93(5):1885-93
pubmed: 8182121
Mol Cell Endocrinol. 2016 Jul 15;430:68-76
pubmed: 27090568
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Can J Cardiol. 2018 May;34(5):632-643
pubmed: 29731023
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Am J Physiol Renal Physiol. 2019 Dec 1;317(6):F1450-F1461
pubmed: 31566426
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
BMJ. 2018 Sep 4;362:k1497
pubmed: 30181166
Lancet. 2002 Mar 23;359(9311):1004-10
pubmed: 11937179
Nat Rev Cardiol. 2017 Oct;14(10):591-602
pubmed: 28492288
N Engl J Med. 2016 Jul 28;375(4):380-2
pubmed: 27331286
Endocrinology. 2015 Mar;156(3):1121-32
pubmed: 25549045
J Biol Chem. 1999 Oct 15;274(42):29905-11
pubmed: 10514472
Diabetes Care. 2004 Aug;27(8):1879-84
pubmed: 15277411
Circulation. 2019 Nov 19;140(21):1693-1702
pubmed: 31434508
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Methods Mol Biol. 2019;1916:203-211
pubmed: 30535697
Lancet. 2000 Jan 22;355(9200):253-9
pubmed: 10675071
N Engl J Med. 2010 Jan 28;362(4):361-2
pubmed: 20107223
Diabetes Ther. 2020 Dec;11(12):2791-2827
pubmed: 33025397
Curr Med Res Opin. 2019 Jul;35(7):1283-1295
pubmed: 30767677
Diabetes Care. 2002 Mar;25(3):471-5
pubmed: 11874932
Int J Med Sci. 2017 Jun 23;14(7):698-704
pubmed: 28824303
Diabetes. 2000 Dec;49(12):2178-89
pubmed: 11118023
J Diabetes Res. 2018 Apr 10;2018:2974304
pubmed: 29850600
Circ Heart Fail. 2009 Mar;2(2):129-37
pubmed: 19808328
Stem Cells. 2013 Nov;31(11):2408-19
pubmed: 23922321
Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711
pubmed: 32862232